World-class
Scientific Advisory

Work with Richmond Pharmacology and trust your experience will be personal and truly strategic.

Dr Jorg Taubel, MD FFPM
Chief Executive Officer

Dr Jorg Taubel is a medical practitioner and CEO of Richmond Pharmacology which he co-founded in 2001. He has worked in clinical pharmacology for over 25 years and during that time he has conducted more than 400 early phase studies in patients and healthy volunteers; usually in the capacity of Principal Investigator since 1995. His experience ranges from first time in man (FTIM) to proof of concept (POC) studies. He has extensive experience in cardiology, neurology, gastroenterology, ethnic bridging studies.

His work currently focusses on providing expert advice in cardiac safety assessments and ethnic comparison studies. Dr Taubel is an honorary fellow at St George's University and author of over 50 publications in scientific journals. He is currently researching the role of hyperglycaemia in relation to sudden cardiac death in Type I diabetic patients. He presented his research at numerous international meetings and workshops in Europe, US and Japan.

Dr Taubel is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom and the Institute of Directors (IOD). He is a Regent in the Arbeitsgemeinschaft Angewandte Humanpharmakologie (AGAH). He is a member of the (British) Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI) and the Royal Society of Medicine. His international memberships include the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT), the American College of Clinical Pharmacology (ACCP).

He is currently representing CCRA in the MHRA stakeholder discussions reviewing the MHRA Phase I Accreditation Scheme for clinical trials units in the UK. Since 1999 he has been involved in the design, programming and implementation of a pan-European research volunteer registry, designed to prevent study participants from oversubscribing to clinical studies.

He teaches on the AGAH course in Basic Pharmacology in Germany and an internal training program for junior doctors working at Richmond Pharmacology enrolled in Higher Medical Training in Pharmaceutical Medicine. He is actively participating in discussions to set up a pan-European training scheme for principal investigators jointly with the Faculty of Pharmaceutical Medicine currently involving societies in the UK, France, Belgium and Germany. He is an appraiser in the Faculty of Pharmaceutical Medicine.

Back to experts
r-gate

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

October 20, 2020
Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)
Read more

Richmond Pharmacology supports ReViral with the development of Sisunatovir

September 9, 2020
ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.
Read more